{"id":"intramuscular-ziprasidone-mesylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL3989833","moleculeType":"Small molecule","molecularWeight":"563.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ziprasidone mesylate is the salt form of ziprasidone designed for intramuscular injection, providing rapid onset of action for acute agitation or psychotic symptoms. By antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors, it reduces positive symptoms of psychosis and agitation while the serotonergic activity may help mitigate extrapyramidal side effects. The intramuscular formulation allows for faster therapeutic effect compared to oral administration.","oneSentence":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:39.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation associated with schizophrenia or bipolar disorder"},{"name":"Schizophrenia (maintenance and acute treatment)"},{"name":"Bipolar disorder (acute mania and maintenance)"}]},"trialDetails":[{"nctId":"NCT00723606","phase":"PHASE3","title":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":376},{"nctId":"NCT00650429","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-10","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":28},{"nctId":"NCT00644800","phase":"PHASE4","title":"A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-07","conditions":"Schizophrenia, Mania, Delusional Disorder","enrollment":89},{"nctId":"NCT03211897","phase":"","title":"Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-06-15","conditions":"Agitation,Psychomotor","enrollment":737},{"nctId":"NCT00786318","phase":"PHASE4","title":"Ziprasidone vs Standard Therapy for Agitated Patients in the ED","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-09","conditions":"Psychosis, Agitation, Delirium","enrollment":""},{"nctId":"NCT02935998","phase":"PHASE4","title":"The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation","status":"UNKNOWN","sponsor":"Yang Fude","startDate":"2016-10","conditions":"Schizophrenia","enrollment":1000},{"nctId":"NCT01485692","phase":"NA","title":"Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Psychomotor Agitation","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zeldox, Geodon"],"phase":"phase_3","status":"active","brandName":"Intramuscular ziprasidone mesylate","genericName":"Intramuscular ziprasidone mesylate","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Acute agitation associated with schizophrenia or bipolar disorder, Schizophrenia (maintenance and acute treatment), Bipolar disorder (acute mania and maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}